December 17, 2018
Sunovion finds positive results in schizophrenia study
Photo/Grant Welker
Marlborough's Sunovion is developing a drug to treat adult schizophrenia and is encouraged by test results.
Marlborough biopharmaceutical company Sunovion says it has found positive results from a study of a treatment for schizophrenia.
Sunovion said patients with adult schizophrenia treated with the proposed new drug showed statistically significant and clinically meaningful improvement compared to a placebo after four weeks of treatment.
The company plans to advance the development of the medicine as quickly as possible, said Antony Loebel, Sunovion's executive vice president and chief medical officer.
The new drug was developed in a partnership with PsychoGenics, a New Jersey drug developer. The two companies said the drug in development would be the first to treat schizophrenia that doesn't bind to dopamine 2 receptors.
WBJ Web Partners
Most Recent
Most Recent
0 Comments